We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Instem Plc | LSE:INS | London | Ordinary Share | GB00B3TQCK30 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 830.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMINS
RNS Number : 7698R
Instem plc
26 September 2017
Instem plc
("Instem", the "Company" or the "Group")
Half Yearly Report
Instem plc (AIM: INS.L), a leading provider of IT solutions to the global life sciences market, announces its unaudited half year results for the six months ended 30 June 2017.
Financial Highlights
-- Total revenues increased 13% to GBP10.3m (H1 2016: GBP9.1m)
-- Recurring revenues increased 23% to GBP6.5m (H1 2016: GBP5.3m), of which SaaS was GBP1.7m (H1 2016: GBP1.2m)
-- Proportion of recurring revenue to total revenue increased to 63% (H1 2016: 58%) -- EBITDA* of GBP0.6m (H1 2016: GBP1.2m) -- Adjusted** profit before tax of GBP0.1m (H1 2016: GBP1.0m) -- Adjusted** basic earnings per share of 0.2p (H1 2016: 6.3p) -- Reported loss before tax of GBP0.6m (H1 2016: profit of GBP0.1m) -- Reported basic loss per share of 4.4p (H1 2016: earnings per share of 0.4p) -- Seasonal net operating cash outflow of GBP1.4m (H1 2016: GBP1.5m)
-- After acquisition related payments of GBP0.5m in H1 2017 and GBP1.7m in H2 2016, net cash balance as at 30 June 2017 of GBP1.2m (H1 2016: GBP4.8m)
*Earnings before interest, tax, depreciation, amortisation and non-recurring items.
**After adjusting for the effect of foreign currency exchange on the revaluation of inter-company balances included in finance income/(costs), non-recurring items and the amortisation of intangibles on acquisitions. Profit is adjusted in this way to provide a clearer measure of underlying operating performance.
Operational Highlights
Significant Strategic progress:
-- Completion of a Group-wide re-organisation to improve efficiency and agility: -- Non-recurring costs of GBP0.3m recognised during the period -- Estimated operational cost savings of GBP1.5m per annum -- Further investment in resources to help secure the opportunity in S
Underlying trading remains strong:
-- Regulatory Solutions Business saw increasing demand from the recently mandated Standard for the Exchange of Nonclinical Data ("S") and continued to increase market share, winning the majority of technology and outsourced services contracts
-- Major expansion of a Study Management contract with the US Government -- Confirmation of the Target Safety Assessment opportunity addressed by our informatics-based KnowledgeScan service
Phil Reason, CEO of Instem plc, commented:
"Following a period of planned strategic progress, Instem is now undoubtedly better positioned for profitable growth than ever before. While our target markets are generally experiencing stability or growth, our focus is moving toward annually recurring revenue and higher margins, with less reliance on perpetual software license sales.
We are particularly excited by the growth potential for our technology-enabled outsourced services for S and Target Safety Assessment where there are increasing regulatory drivers, competitive differentiators and customer activity remains high.
The continued investment in our outsourced services team has increased our monthly revenue generation and the full benefit of the overhead reductions implemented at the end of the first half of the year will also be realised in the second half of 2017 and beyond. Consequently, we anticipate earnings for the full year to be in line with market expectations."
For further information, please contact:
Instem plc +44 (0) 1785 825 600 Phil Reason, CEO www.instem.com Nigel Goldsmith, CFO N+1 Singer (Nominated Adviser & Broker) +44 (0) 20 7496 3000 Richard Lindley Nick Owen Walbrook Financial PR +44 (0) 20 7933 8780 Paul Cornelius instem@walbrookpr.com Sam Allen Helen Cresswell
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.
Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.
Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.
To learn more about Instem solutions and its mission, please visit instem.com.
CHAIRMAN'S STATEMENT
The first half of the current financial year has been a period of strategic development and significant operational change designed to both optimise the current operations and facilitate the future direction of the business. These improvements were completed during the first half of the year and are expected to improve efficiency and profitability in the second half of the current year and beyond.
Over recent years the Company has strengthened and expanded its business through the addition of world leading products and services for new and existing markets and has invested to ensure that we can operate in all relevant global territories.
Since flotation at the end of 2010, we have acquired five businesses, internally developed several additional product lines, widened our operational footprint in Europe and established a sales and customer service presence in China, Japan and India. Furthermore, in addition to our original focus on Study Management, we now address the Regulatory Solutions and Informatics markets. Simultaneously, our revenue model is changing with an increasing emphasis on recurring revenue through a combination of SaaS and technology enabled services.
In the first half of the year, we carried out a review of our operations to consolidate and centralise activities for synergies, where appropriate and ensure they are aligned to capture future growth opportunities. This is expected to result in annual cost savings of approximately GBP1.5m. To effectively manage these centralised activities we have strengthened our top management team with the appointment, in January this year, of Chief Operating Officer, MaryBeth Thompson. MaryBeth has extensive experience in the life sciences industry.
Despite the amount of operational change during the period, total revenues for the six months to June were some 13% higher than the prior year at GBP10.3m (H1 2016: GBP9.1m). In particular, our Regulatory Solutions business continued to develop and, we believe, continued to win the majority of S-related business placed. Our Informatics based KnowledgeScan business also continued to develop with a significant increase in the number of Target Safety Assessment reports being produced during the period. The performance of Study Management was also positive, including the award of a major contract extension for the US Government's National Institute of Environmental Health Sciences and substantially increasing the number of supported Provantis users at our largest client.
The increase in overheads in the period under review over the previous six months was the direct result of both a full six months' cost of the two acquisitions made in 2016 and the continued organic investment in our technology enabled outsourced services business, which required additional resource to meet growing demand. In addition, as a result of further management insight into our Clinical business, following its restructuring at the end of 2016, we have made additional investment in our Alphadas product to ensure that we maintain our strong market position. At the same time, we have made a one-off provision against potential costs arising from historical issues associated with this business.
Whilst EBITDA for the period at GBP0.6m was below earlier expectations, the second half will benefit from approximately GBP750k of cost savings. As a result of our operational improvements and success in securing anticipated new business, we expect a satisfactory outcome to the year as a whole.
David Gare, Non-Executive Chairman
25 September 2017
CHIEF EXECUTIVE'S REPORT
Strategic Development
The period under review was one of significant operational change and strategic progress. The arrival of our new Chief Operating Officer, MaryBeth Thompson at the start of the period, provided the opportunity to trigger the next stage of business reorganisation and integration. This saw the creation of centralised areas of excellence for all key operational functions under a new Operations leadership team, comprising new hires and existing experienced managers. The increased senior management team bandwidth has allowed us to analyse the opportunities, challenges and threats facing the business and also provided valuable insights into the Company's industry position and future opportunities. The process identified areas of the business where there was capacity that could be redeployed or reduced and enabled a number of out-sourced activities to be more cost-effectively delivered in-house, using UK and India based resources. This has all been achieved whilst ensuring the business remained agile and responsive to the dynamic markets in which it operates.
The Company has successfully reduced its annual overheads by approximately GBP1.5m or 10%, which should significantly improve the Group's profitability in the second half of the current year and beyond.
Whilst this transition obviously created some disruption within the business during the period, senior management continued to focus on driving higher quality recurring revenues, which now represent 63% of total revenues. Recurring revenues now cover approximately 68% of total overheads providing much greater visibility into the future financial performance of the business and support for our longer term investment decisions.
As a result of these actions, we believe that Instem is now 'purpose built' to deliver software and scientific services which address three distinct, but complementary, value propositions:
1. To efficiently capture, record and analyse scientific study data
2. To generate new insights from existing large data sets through the application of sophisticated informatics
3. To ensure compliance with global regulators such as the FDA, EPA etc
Instem products and services now address the entire drug development value chain, from discovery through to market launch, and are currently deployed by over 500 companies, including all the largest 25 pharmaceutical companies in the world.
Market Review
During the period Instem continued to win the majority of new business placed in Non-clinical, our largest market. However, while the order volume increased, the provision of client data for our out-sourced S services contracts was slower than projected, with much of the market leaving compliance with the December 2016 mandated regulatory standard until much later in the year than anticipated.
Study Management and Data Collection
The global market for software to ensure the efficient capture, recording and analysis of scientific study data remains robust as the number of compounds in Research and Development continues to increase. According to a recent report from Informa's Pharma Intelligence, a leading industry and market analysis firm, the number of compounds in the Global R&D Pipeline increased by 8.4% to 14,749 in 2017, its highest ever number. We believe that this is due to a number of factors, but the overall trend is largely underpinned by global population growth and from increasing life expectancy, which is unlikely to change over the near-term.
Importantly, the number of compounds in the R&D Pipeline within Pre-Clinical and Phase I trials, where Instem specialises, has increased year on year by 9.2% and 11.2% respectively, indicating a growing potential for the Company's products and services within these market segments.
The Company is particularly pleased to report that its contract with the National Institute of Environmental Health Sciences ("NIEHS ") has progressed well since it was first announced in 2013. This 10-year contract for the capture, recording and analysis of pre-clinical safety evaluation study data, as anticipated, has expanded in scope since commencement, with the number of locations and the number of authorised users both increasing over the period, further demonstrating the increasing value of the Company's software and services to the NIEHS.
Our largest customer also brought into operation over 700 additional Provantis user licenses during 2017 triggering enhanced recurring revenue.
Our genetic toxicology solutions continue to dominate their market and with a new release of our Cyto Study Manager solution we anticipate further cross-selling opportunities across additional Instem key accounts.
The Notocord business acquired in September 2016 has integrated well and made a solid contribution during the period. A particular highlight was a large order for the U.S. Army Medical Research Institute of Infectious Diseases.
The new business pipeline remains promising, although during the period the focus of our Study Management and Data Collection business has been predominantly on completing implementation projects for existing clients with some notable success. Following the conclusions of our review and re-structure, significant software development investment continues to be made in Alphadas to ensure that we continue to secure a sizeable market share in a competitive market.
Informatics
The KnowledgeScan(TM) informatics-based service was piloted in 2015 and formally launched by the Company in 2016. It offers the pharmaceutical industry insightful new ways to create value from huge volumes of public and proprietary scientific and health-related data to reduce the risk and cost of bringing new drugs to market.
The initial application of KnowledgeScan is for Target Safely Assessment ("TSA"), a process routinely undertaken at the earlier stages of drug discovery, but with continuing value throughout the drug development process. Business volume has grown well in 2017, having completed more TSAs in the first half of 2017 than in the full year of 2016, with the pace of increase in activity being sustained into the third quarter of 2017. We have added some resource, but TSA capacity has generally been increased through further process automation. Repeat business remains encouraging with over 80% of customers having already placed further orders.
Regulatory Solutions
Regulatory Solutions represent a growing market opportunity for Instem with a broad target market in Regulatory Information Management ("RIM") and growing demand for our regulatory submission related products and services that implement the FDA mandated Standard for Exchange of Non-clinical Data ("S").
Regulatory Information Management
The integration of Samarind, which we acquired in 2016, is now largely complete and, having identified specific areas of the RIM market where we have market leading capabilities, we are actively pursuing related opportunities. We were pleased to secure an order with one of the world's top 10 medical device businesses for the entire Samarind RMS suite during the period. The industry and regulatory initiative to implement an internationally harmonised standard for the Identification of Medicinal Products ("IDMP") has been delayed by several years, but it remains of keen interest to our current customers and prospects given our leadership in implementing the current European standard, which will ultimately be replaced.
Standard for the Exchange of Nonclinical Data ("S")
Instem continues to dominate the S technology market with software sales during the period predominantly focussed on our modules for "viewing" or "exploring" S datasets. With the first regulatory mandate coming into force in December 2016, those companies who hadn't already equipped themselves with the technology to "create" S datasets are now predominantly looking for out-sourced services for S creation. While we have won the large majority of out-sourced services contracts, many clients have then been slow to provide data for conversion. This is expected to pick up during the second half of 2017.
During 2017, enquiries for the Company's software solutions in general and its outsourcing services in particular have continued to increase as the next major milestone of the S mandate goes into effect during December 2017. This covers shorter duration studies that are undertaken in much greater volume and so is expected to generate a significant increase in S conversion demand.
During the first seven months of 2017, the Group has received a total of 54 orders from 38 organisations, of which 19 were first-time Instem customers.
Instem now has a total of 71 customers that have procured the Company's S technology and/or out-sourced services, which include eight of the top 10 pre-clinical CROs and 17 of the world's top 25 global pharmaceutical companies. Established S-related client relationships are expected to be a significant source of future business as the volume of out-sourced services increases.
During 2017, the Group introduced a new software module, STrial(TM), that will deliver significant efficiencies for its clients (and our internal Services team) by reducing processing time in one specific area by up to 80%. This product is the first of its type on the market and offers a solution which can be deployed alongside Instem's existing submit(TM) products or used independently. STrial(TM) will create additional opportunities for Instem with those companies that are currently running competing systems that cannot efficiently meet these specific requirements.
In addition, Instem has released an updated version of its submit(TM) software that enables clients to satisfy an FDA request for test data supporting the development of the next version of the standard. No other vendor in the marketplace has introduced this capability and this clearly gives Instem first mover advantage in this rapidly growing market segment.
Outlook
Following a period of planned strategic progress, Instem is now undoubtedly better positioned for profitable growth than ever before. While our target markets are generally experiencing stability or growth, our focus is moving toward annually recurring revenue and higher margins, with less reliance on perpetual software license sales.
We are particularly excited by the growth potential for our technology-enabled outsourced services for S and Target Safety Assessment where there are increasing regulatory drivers, competitive differentiators and customer activity remains high.
The continued investment in our outsourced services team has increased our monthly revenue generation and the full benefit of the overhead reductions implemented at the end of the first half of the year will also be realised in the second half of 2017 and beyond. Consequently, we anticipate earnings for the full year to be in line with market expectations.
Phil Reason, Chief Executive
25 September 2017
CHIEF FINANCIAL OFFICER'S REVIEW
Instem's revenue model consists of a blend of fees for perpetual licences with annual support fees, SaaS subscriptions and professional services income. As previously stated, significant growth potential is seen for outsourced professional services for S and KnowledgeScan with customers now starting to place increasing levels of repeat business.
Total revenues increased 13% from GBP9.1m to GBP10.3m in the period. Recurring revenue, derived from annual support fees, SaaS subscriptions and outsourced managed services, increased 23% to GBP6.5m (H1 2016: GBP5.3m) or 63% (H1 2016: 58%) of total revenue.
Operating expenses were GBP1.9m higher in the period at GBP9.6m compared with GBP7.7m in H1 2016. The increase primarily related to the full 6 month cost impact of the recently acquired companies together with the full cost of the investment in key staff recruited in the second half of 2016.
The reorganisation exercise carried out at the end of the period resulted in non-recurring costs of GBP0.3m and an estimated operational cost saving of GBP0.75m in the second half of 2017, which increases to GBP1.5m per annum in future years.
Development expenditure in the period was GBP1.7m (H1 2016: GBP0.7m), of which GBP0.9m was capitalised (H1 2016: GBP0.1m). Importantly, a significant proportion of the new development costs related to the continued investment in our Study Management and Data Collection software as well as reflecting integration of the newly acquired products from the Notocord and Samarind acquisitions.
Earnings from operations before interest, tax, depreciation, amortisation and non-recurring items, ('EBITDA') for the period, were GBP0.6m (H1 2016: GBP1.2m). Depreciation and amortisation increased to GBP0.8m compared with GBP0.5m in the equivalent prior period. The majority of the change relates to acquired intangibles in 2016.
Non-recurring costs include GBP0.3m of reorganisation costs and a GBP0.3m provision against potential costs arising from historical issues relating to Instem Clinical. Non-recurring income of GBP0.1m arose from an adjustment to the contingent consideration payable in respect of the 2016 acquisitions.
The IAS19 funding deficit on Instem's defined benefit pension scheme decreased by a net GBP0.5m to GBP4.2m during the period, primarily due to lower expectations of future inflation, positive asset returns and employer deficit contributions.
In the first half of 2016 the Company raised GBP5.0m to fund acquisitions. The subsequent Samarind and Notocord acquisitions consumed the majority of those funds through payment of initial, deferred and contingent consideration during 2016 and a further GBP0.5m in H1 2017.
Instem's operating cash flow continues to reflect normal seasonality within the business, with cash inflow being more weighted towards the second half of the year, when annual fee renewals normally occur prior to the beginning of the new calendar year. Net cash at the end of June 2017 totalled GBP1.2m (H1 2016 GBP4.8m).
Share capital, share premium and merger reserve increased by GBP0.2m in the period due to shares issued to settle a proportion of the consideration payable on the acquisitions.
In line with previous periods, and given our existing policy of retaining cash within the business to capitalise on available growth opportunities, the Board has not recommended the payment of a dividend.
Principal risks and uncertainties
The principal risks and uncertainties within the business remain unchanged from those described in our 2016 Annual Report.
Nigel Goldsmith, Chief Financial Officer
25 September 2017
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For the six months ended 30 June 2017
Hot Features
Premium
Unaudited Unaudited Audited
Six months Six months Year
ended ended ended 31
30 June 30 June December 2016
2017 2016 GBP000
Notes GBP000 GBP000
REVENUE 10,278 9,052 18,319
Operating expenses (9,644) (7,699) (16,843)
Share based payment (46) (154) (223)
EARNINGS BEFORE INTEREST, TAXATION, DEPRECIATION,
AMORTISATION AND NON-RECURRING ITEMS ("EBITDA") 588 1,199 1,253
Depreciation (97) (77) (156)
Amortisation of intangibles arising on acquisition (466) (268) (667)
Amortisation of internally generated intangibles (225) (157) (380)
--------------- ---------------- ---------------
(LOSS)/PROFIT BEFORE NON-RECURRING COSTS (200) 697 50
Non-recurring (costs)/income 4 (426) (126) 619
--------------- ---------------- ---------------
(LOSS)/PROFIT AFTER NON-RECURRING COSTS AND BEFORE
FINANCE COSTS (626) 571 669
Finance income 5 167 3 -
Finance costs 6 (168) (446) (646)
--------------- ---------------- ---------------
(LOSS)/PROFIT BEFORE TAXATION (627) 128 23
Taxation (73) (67) 1,035
--------------- ---------------- ---------------
(LOSS)/PROFIT FOR THE PERIOD (700) 61 1,058
--------------- ---------------- ---------------
OTHER COMPREHENSIVE INCOME/(EXPENSE)
Items that will not be reclassified to profit and loss
account
Actuarial gain/(loss) on retirement benefit obligations 333 (875) (1,192)
Deferred tax on actuarial (gain)/loss (57) 157 215
--------------- ---------------- ---------------
276 (718) (977)
Items that may be reclassified to profit and loss
account
Exchange differences on translating foreign operations (480) 454 844
--------------- ---------------- ---------------
OTHER COMPREHENSIVE EXPENSE FOR THE PERIOD (204) (264) (133)
--------------- ---------------- ---------------
TOTAL COMPREHENSIVE (EXPENSE)/INCOME FOR THE PERIOD (904) (203) 925
=============== ================ ===============
(LOSS)/PROFIT ATTRIBUTABLE TO OWNERS OF THE PARENT
COMPANY (700) 61 1,058
=============== ================ ===============
TOTAL COMPREHENSIVE (EXPENSE)/INCOME ATTRIBUTABLE TO
OWNERS OF THE PARENT COMPANY (904) (203) 925
=============== ================ ===============
Earnings per Share from continuing operations
attributable to owners of the parent
- Basic 3 (4.4p) 0.4p 6.9p
-
Diluted 3 (4.4p) 0.4p 6.8p
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As at 30 June 2017
Unaudited Unaudited Audited
30 June 30 June 31 December
2017 2016 2016
Notes GBP000 GBP000 GBP000
ASSETS
NON-CURRENT ASSETS
Intangible assets 17,996 14,390 17,607
Property, plant and
equipment 376 359 374
Deferred tax assets 506 534 947
---------- ---------- ------------
TOTAL NON-CURRENT ASSETS 18,878 15,283 18,928
---------- ---------- ------------
CURRENT ASSETS
Inventories 62 1,045 916
Trade and other receivables 6,698 6,371 6,899
Financial asset - - 10
Cash and cash equivalents 7 1,165 4,755 4,189
---------- ---------- ------------
TOTAL CURRENT ASSETS 7,925 12,171 12,014
---------- ---------- ------------
TOTAL ASSETS 26,803 27,454 30,942
========== ========== ============
LIABILITIES
CURRENT LIABILITIES
Trade and other payables 3,206 2,237 2,670
Deferred income 6,598 6,897 9,092
Current tax payable 19 599 429
Financial liabilities 389 1,118 979
---------- ---------- ------------
TOTAL CURRENT LIABILITIES 10,212 10,851 13,170
---------- ---------- ------------
NON-CURRENT LIABILITIES
Financial liabilities 69 600 242
Retirement benefit obligations 4,166 4,511 4,746
Provision for liabilities
and charges 8 250 - -
---------- ---------- ------------
TOTAL NON-CURRENT LIABILITIES 4,485 5,111 4,988
---------- ---------- ------------
TOTAL LIABILITIES 14,697 15,962 18,158
========== ========== ============
EQUITY
Share capital 1,587 1,571 1,577
Share premium 12,466 12,373 12,462
Merger reserve 1,598 1,432 1,432
Shares to be issued 910 686 864
Translation reserve 568 658 1,048
Retained earnings (5,023) (5,228) (4,599)
-------- -------- --------
TOTAL EQUITY ATTRIBUTABLE
TO OWNERS OF THE PARENT 12,106 1,492 12,784
-------- -------- --------
TOTAL EQUITY AND LIABILITIES 26,803 27,454 30,942
======== ======== ========
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
For the six months ended 30 June 2017
Unaudited Unaudited Audited
Six months ended 30 June Six months ended 30 June Year ended 31 December
2017 2016 2016
GBP000 GBP000 GBP000
CASH FLOWS FROM OPERATING
ACTIVITIES
Loss/(profit) before taxation (627) 128 23
Adjustments for:
Depreciation 97 77 156
Loss on disposal of property, plant
and equipment - - 2
Amortisation of intangibles 691 425 1,047
Share based payment 46 154 223
Retirement benefit obligations (312) (367) (518)
Finance income (167) (3) -
Finance costs 168 446 646
Decrease in deferred contingent
consideration (148) - (1,017)
------------------------- ------------------------- -----------------------
CASH FLOWS FROM OPERATIONS BEFORE
MOVEMENTS IN WORKING CAPITAL (252) 860 562
Movements in working capital:
Decrease/(increase) in inventories 678 (156) 12
Increase in trade and other
receivables (310) (599) (1,737)
(Decrease)/increase in trade, other
payables and deferred income (1,796) (1,663) 1,810
Increase in provisions 250 - -
------------------------- ------------------------- -----------------------
CASH (USED IN)/GENERATED FROM
OPERATIONS (1,430) (1,558) 647
Finance income 167 - -
Finance costs (44) (9) (379)
Income taxes (102) 42 (141)
------------------------- ------------------------- -----------------------
NET CASH (USED IN)/GENERATED FROM
OPERATING ACTIVITIES (1,409) (1,525) 127
------------------------- ------------------------- -----------------------
CASH FLOWS FROM INVESTING ACTIVITIES
Finance income received - 3 -
Purchase of intangible assets (921) (138) (890)
Purchase of property, plant and equipment (103) (39) (113)
Payment of deferred contingent consideration (496) - -
Repayment of capital from finance leases (15) (18) (33)
Purchase of subsidiary undertakings (net of cash acquired) - (616) (2,347)
--------- ------- --------
NET CASH USED IN INVESTING ACTIVITIES (1,535) (808) (3,383)
--------- ------- --------
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issue of share capital 5 4,728 4,823
Finance lease interest (4) (5) (8)
--------- ------- --------
NET CASH GENERATED FROM FINANCING ACTIVITIES 1 4,723 4,815
--------- ------- --------
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS (2,943) 2,390 1,559
Cash and cash equivalents at start of period 4,189 2,183 2,183
Effect of exchange rate changes on the balance of cash held in foreign currencies (81) 182 447
--------- ------- --------
CASH AND CASH EQUIVALENTS AT OF PERIOD 1,165 4,755 4,189
========= ======= ========
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the six months ended 30 June 2017
Attributable to owners of the parent
Called Share Merger Shares to be Translation Retained Total
up share premium reserve issued reserve earnings equity
capital
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
Balance as at 31
January 2016
(audited) 1,304 7,903 1,241 641 204 (4,680) 6,613
Profit for the
period - - - - - 61 61
Other
comprehensive
income/(expense) - - - - 454 (718) (264)
--------- ---------- --------- -------------- ------------ ---------- --------
Total
comprehensive
income/(expense) - - - - 454 (657) (203)
Shares issued 267 4,470 191 (109) - 109 4,928
Share based
payment - - - 154 - - 154
--------- ---------- --------- -------------- ------------ ---------- --------
Balance as at 30
June 2016
(unaudited) 1,571 12,373 1,432 686 658 (5,228) 11,492
Profit for the
period - - - - - 997 997
Other
comprehensive
income/(expense) - - - - 390 (259) 131
--------- ---------- --------- -------------- ------------ ---------- --------
Total
comprehensive
income - - - - 390 738 1,128
Shares issued 6 89 - 109 - (109) 95
Share based
payment - - - 69 - - 69
--------- ---------- --------- -------------- ------------ ---------- --------
Balance as at 31
December 2016
(audited) 1,577 12,462 1,432 864 1,048 (4,599) 12,784
Loss for the
period - - - - - (700) (700)
Other
comprehensive
(expense)/income - - - - (480) 276 (204)
--------- ---------- --------- -------------- ------------ ---------- --------
Total
comprehensive
expense - - - - (480) (424) (904)
Shares issued 10 4 166 - - - 180
Share based
payment - - - 46 - - 46
--------- ---------- --------- -------------- ------------ ---------- --------
Balance as at 30
June 2017
(unaudited) 1,587 12,466 1,598 910 568 (5,023) 12,106
========= ========== ========= ============== ============ ========== ========
NOTES TO THE FINANCIAL INFORMATION
For the six months ended 30 June 2017
GENERAL INFORMATION
The principal activity and nature of operations of the Group is the provision of world class IT solutions to the early development healthcare market. Instem's solutions for data collection, management and analysis are used by customers worldwide, to meet the needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products. Instem plc is a public limited company, listed on AIM, and incorporated in England and Wales under the Companies Act 2006 and domiciled in England and Wales. The registered office is Diamond Way, Stone Business Park, Stone, Staffordshire, ST15 0SD.
Notes to the accounts
1. Basis of preparation and accounting policies
Basis of preparation
The Group's half-yearly financial information, which is unaudited, consolidates the results of Instem plc and its subsidiary undertakings made up to 30 June 2017. The Group's accounting reference date is 31 December.
The consolidated financial information is presented in Pounds Sterling (GBP) which is also the functional currency of the parent.
The financial information contained in this half-yearly financial report does not constitute statutory accounts as defined in section 434 of the Companies Act 2006. It does not therefore include all of the information and disclosures required in the annual financial statements.
The financial information for the six months ended 30 June 2016 and 30 June 2017 is unaudited.
Instem plc's consolidated statutory accounts for the year ended 31 December 2016, prepared under IFRS, have been delivered to the Registrar of Companies. The report of the auditors on these accounts was unqualified and did not contain a statement under Section 498 (2) or (3) of the Companies Act 2006.
Significant accounting policies
The accounting policies used in the preparation of the financial information for the six months ended 30 June 2017 are in accordance with the recognition and measurement criteria of International Financial Reporting Standards ('IFRS') as adopted by the European Union and are consistent with those which will be adopted in the annual statutory financial statements for the year ending 31 December 2017.
While the financial information included has been prepared in accordance with the recognition and measurement criteria of International Financial Reporting Standards (IFRS), as adopted by the European Union (EU), these financial statements do not contain sufficient information to comply with IFRS's.
Instem plc and its subsidiaries have not applied IAS 34, Interim Financial Reporting, which is not mandatory for UK AIM listed groups, in the preparation of this half-yearly financial report.
Cash and cash equivalents
Cash and cash equivalents for the purposes of the Statement of Cash Flows comprise the net of cash and overdraft balances that are shown on the Statement of Financial Position in Cash and Cash Equivalents.
2. Segmental Information
The Directors consider that the Group operates in one business segment - Global Life Sciences, and therefore there are no additional segmental disclosures to be made in these financial statements.
3. Earnings per share
Basic earnings per share are calculated by dividing the (loss)/profit attributable to ordinary shareholders by the weighted average number of ordinary shares in issue during the year. Diluted earnings per share is calculated by adjusting the weighted number of ordinary shares outstanding to assume conversion of all dilutive potential shares arising from the share option scheme. The dilutive impact of the share options is calculated by determining the number of shares that could have been acquired at fair value (determined as the average market share price of the Company's shares) based on the monetary value of the subscription rights attached to the outstanding share options.
(a) Basic
Six months Six months Year
ended ended ended
30 June 30 June 31 December
2017 2016 2016
Unaudited Unaudited Audited
(Loss)/profit after
tax (GBP000) (700) 61 1,058
----------- ----------- -------------
Weighted average number
of shares (000's) 15,785 14,865 15,302
----------- ----------- -------------
Basic (loss)/earnings
per share (4.4p) 0.4p 6.9p
=========== =========== =============
(b) Diluted
Six months Six months Year
ended ended ended
30 June 30 June 31 December
2017 2016 2016
Unaudited Unaudited Audited
(Loss)/profit after
tax (GBP000) (700) 61 1,058
----------- ----------- -------------
Weighted average number
of shares (000's) 15,785 14,865 15,302
Potentially dilutive
shares (000's) -* 384 324
Adjusted weighted average
number of shares (000's) 15,785 15,249 15,626
----------- ----------- -------------
Diluted (loss)/earnings
per share (4.4p) 0.4p 6.8p
=========== =========== =============
*Dilutive share options have been excluded from the calculations in accordance with IAS33 - 'Earnings per share' as they are only included where the impact is dilutive.
(c) Adjusted
Adjusted earnings per share is calculated after adjusting for the effect of foreign currency exchange on the revaluation of inter-company balances included in finance income/(costs), non-recurring items and amortisation of intangibles on acquisitions. Diluted adjusted earnings per share is calculated by adjusting the weighted number of ordinary shares outstanding to assume conversion of all dilutive potential shares arising from the share option scheme. The dilutive impact of the share options is calculated by determining the number of shares that could have been acquired at fair value (determined as the average market share price of the Company's shares) based on the monetary value of the subscription rights attached to the outstanding share options.
Year
Six months Six months ended
ended ended 31 December
30 June 2017 30 June 2016
Unaudited 2016 Unaudited Audited
(Loss)/profit after
tax (GBP000) (700) 61 1,058
Non-recurring costs/(income)
(GBP000) 426 126 (619)
Amortisation of acquired
intangibles (GBP000) 466 268 667
Foreign exchange differences
on revaluation of intergroup
balances (GBP000) (159) 476 646
-------- ------------- -------
Adjusted profit after
tax (GBP000) 33 931 1,752
-------- ------------- -------
Weighted average number
of shares (000's) 15,785 14,865 15,302
Potentially dilutive
shares (000's) 201 384 324
-------- ------------- -------
Adjusted weighted average
number of shares (000's) 15,986 15,249 15,626
-------- ------------- -------
Adjusted basic earnings
per share 0.2p 6.3p 11.5p
======== ============= =======
Adjusted diluted earnings
per share 0.2p 6.1p 11.2p
======== ============= =======
4. Non-recurring (costs)/income
Six months
ended Six months Year ended
30 June ended 31 December
2017 30 June 2016
Unaudited 2016 Unaudited Audited
GBP000 GBP000 GBP000
Professional fees in
respect of acquisitions - (126) (249)
Amendment to consideration
payable in respect
of Instem Clinical - - 690
Cost provision relating
to historical issues
associated with Instem
Clinical (250) - -
Restructuring costs (324) - (149)
Amendment to contingent
consideration post
acquisition in respect
of Notocord and Samarind 148 - 327
----------- ---------------- -------------
(426) (126) 619
----------- ---------------- -------------
5. Finance income
Six months Year
ended Six months ended
30 June ended 31 December
2017 30 June 2016
Unaudited 2016 Unaudited Audited
GBP000 GBP000 GBP000
Foreign exchange gains 167 3 -
=========== ================ =============
6. Finance costs
Six months Year
ended Six months ended
30 June ended 31 December
2017 30 June 2016
Unaudited 2016 Unaudited Audited
GBP000 GBP000 GBP000
Bank loans and overdrafts 44 9 32
Unwinding discount on
deferred consideration 56 11 120
Net interest on pension
scheme 64 70 139
Foreign exchange losses - 351 347
Finance lease interest 4 5 8
----------- ---------------- -------------
168 446 646
=========== ================ =============
7. Cash and cash equivalents
30 June 31 December
2017 30 June 2016
Unaudited 2016 Unaudited Audited
GBP000 GBP000 GBP000
Cash at bank 10,163 13,753 13,187
Bank overdraft (8,998) (8,998) (8,998)
1,165 4,755 4,189
=========== ================ ============
8. Provision for liabilities and charges
30 June 31 December
2017 30 June 2016
Unaudited 2016 Unaudited Audited
GBP000 GBP000 GBP000
At beginning of the - - -
period
Increase in provisions 250 - -
At end of period 250 - -
=========== ================ ============
The provision relates to potential costs arising from historical issues associated with Instem Clinical (see note 4).
9. Availability of this Interim Announcement
Copies of the Interim Report will shortly be available to download from the Group's website or available to order from the registered office of the Group.
INDEPENDENT REVIEW REPORT TO INSTEM PLC
Introduction
We have been engaged by the Company to review the condensed set of financial statements in the interim financial report for the six months ended 30 June 2017 which comprises of the Condensed Consolidated Statement of Comprehensive Income, Condensed Consolidated Statement of Financial Position, Condensed Consolidated Statement of Cash Flows, Condensed Consolidated Statement of Changes in Equity and the related explanatory Notes that have been reviewed. We have read the other information contained in the interim financial report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements.
This report is made solely to the Company in accordance with International Standard on Review Engagements (UK and Ireland) 2410 "'Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Auditing Practices Board. Our review work has been undertaken so that we might state to the Company those matters we are required to state to them in an independent review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company, for our review work, for this report, or for the conclusions we have formed.
Directors' Responsibilities
The interim financial report, is the responsibility of, and has been approved by the directors. The directors are responsible for preparing and presenting the interim financial report in accordance with the AIM Rules of the London Stock Exchange.
As disclosed in note 1, the annual financial statements of the Group are prepared in accordance with International Financial Reporting Standards and International Financial Reporting Interpretations Committee pronouncements as adopted by the European Union. The condensed set of financial statements included in this interim financial report has been prepared in accordance with the presentation, recognition and measurement criteria of International Financial Reporting Standards and International Financial Reporting Interpretations Committee pronouncements, as adopted by the European Union.
Our Responsibility
Our responsibility is to express to the Company a conclusion on the condensed set of financial statements in the interim financial report based on our review.
Scope of Review
We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Auditing Practices Board for use in the United Kingdom. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK and Ireland) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
Conclusion
Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed set of financial statements in the interim financial report for the six months ended 30 June 2017 is not prepared, in all material respects, in accordance with the presentation, recognition and measurement criteria of International Financial Reporting Standards and International Financial Reporting Interpretations Committee pronouncements as adopted by the European Union, and the AIM Rules of the London Stock Exchange.
RSM UK Audit LLP
Chartered Accountants
14th Floor
Chapel Street
Liverpool
L3 9AG
25 September 2017
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR DGGDCDDDBGRU
(END) Dow Jones Newswires
September 26, 2017 02:01 ET (06:01 GMT)
1 Year Instem Chart |
1 Month Instem Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
